12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

H1N1 SynCon universal influenza vaccine: Interim Phase I data

Inovio Pharmaceuticals Inc. (NYSE-M:INO), Blue Bell, Pa.
Product: H1N1 SynCon universal influenza vaccine
Business: Infectious
Molecular target: NA
Description: Synthetic DNA consensus influenza (H1N1) vaccine
Indication: Vaccinate against H1N1 influenza virus
Endpoint: Safety and immunogenicity
Status: Interim Phase I data
Milestone: Additional...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >